Pre-earnings brief
Reports
Wed, Nov 4, 2026
Est. EPS
—
Est. revenue
—
Implied move
±14.6%
EPS beat rate
88%
Ionis Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases. With a market cap of $7 billion, it operates in the health care sector, aiming to address unmet medical needs through its advanced drug discovery platform.
Last quarter
In Q2-2026, Ionis reported an EPS of -$0.69, outperforming estimates by 36.46%. However, the stock fell by 2.28% the following day, indicating mixed investor sentiment.
EPS beat streak
2Q
EPS beat rate
88%
Avg EPS surprise
+50.25%
Avg 1-day reaction
+0.27%
Analysts are uncertain about Ionis's upcoming earnings, as there are no analyst estimates available. The market is watching closely for any updates on the company's drug pipeline and financial performance.
Bull case
If Ionis can demonstrate strong pipeline advancements and better-than-expected EPS, it could lead to a positive reaction from investors, boosting the stock price.
Bear case
Conversely, if the company fails to meet expectations or provides disappointing updates on its pipeline, it could lead to a significant drop in stock price.
The print will turn on these.
Q1
What updates will be provided on the drug pipeline and any upcoming clinical trials?
Investors will closely evaluate the progress of the pipeline as it directly impacts future revenue potential and company valuation.
Q2
How does management plan to address the recent EPS performance and expectations moving forward?
Understanding management's strategy for improving profitability will be crucial for investor confidence.
—
Est. EPS
$-0.50
Est. Rev
$257M
Impl. Move
±7.5%
Why consensus could be wrong
The Street may be underestimating the potential for Ionis to leverage its pipeline advancements into stronger-than-expected results this quarter.
Supporting evidence
The company's historical EPS surprise rate is high at 88%, indicating a tendency to outperform expectations.
Options pricing suggests a significant move, which may reflect investor anticipation of positive news.
Recent performance trends show that the company has consistently surprised to the upside.
Key risk
If the pipeline updates indicate strong progress, it could challenge the current cautious sentiment.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around the company's ability to translate its pipeline into financial success and investor confidence.
Bull confirmed if
A significant update on pipeline advancements or a positive EPS surprise could confirm the bull case.
Bear confirmed if
Failure to provide clarity on the pipeline or another EPS miss would confirm the bear case.
What the market is pricing for the move.
Implied Move
±8.78%
Historical Avg
±2.8%
The options market is pricing in a substantial move, indicating that investors expect significant volatility around the earnings report.
Options are pricing ±14.6% while IONS has averaged ±2.8% over the last 8 prints — setup is pricing rich.
ATM IV
0.5%
30d HV
44.3%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 11 of 30 (37%)
This setup has occurred 30 times across Health Care in the last 2 years. 19 of 30 (63%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 3.2%, with a raw directional average of -0.6% (modestly negative historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
110.37%
of float
Insider
0.61%
of float
Holders
719
institutions
Top Holders· as of Jun 2026
FMR, LLC
24,631,956 sh · $1.1B
14.82%
0.3%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Ionis beats expectations, history suggests a potential stock increase of around 1.06%, confirming positive sentiment.
In line / cautious
If results are in line but cautious commentary is provided, the stock may experience muted movement as investors reassess.
Miss
A miss could lead to a decline of about 5.29%, reflecting disappointment in the company's performance.
The lines on the call that would change the story.
Capital World Investors
21,669,226 sh · $956.9M
13.04%
2.3%
Blackrock Inc.
10,704,660 sh · $472.7M
6.44%
2.5%
Vanguard Portfolio Management LLC
7,859,529 sh · $347.1M
4.73%
0.6%
Wellington Management Group, LLP
7,651,415 sh · $337.9M
4.60%
19.7%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.